Abstract:DRD1 is expressed in normal lung respiratory epithelial cells, and its expression is reduced in NSCLC tumor tissues at least partially through promoter methylation. In lung cancer cells, DRD1 signaling reduces proliferation through reduced EGFR signaling, and it also reduces PD‐L1 expression. Impaired DRD1 signaling has the opposite effect. Dopamine (DA) acts in various key neurological and physiological processes as both a neurotransmitter and circulating hormone. Over the past several decades, the DA signaling network has been shown to regulate the progression of several types of solid tumors, and considerable evidence has shown it is a druggable pathway in the cancer cell context. However, the specific activity and effect of these pathway components appears to be tissue‐type and cell‐context‐dependent. In the present study, expression and methylation of dopamine receptor D1 (DRD1) were measured using RNA sequencing (RNAseq) and reverse transcription polymerase chain reaction (RT‐PCR) in non‐small cell lung cancer (NSCLC) samples, and validated using publicly available datasets, including The Cancer Genome Atlas (TCGA). In vitro and in vivo functional experiments were performed for cell proliferation and tumor growth, respectively. Mechanistic analyses of the transcriptome and kinome in DRD1‐modulated cells informed further experiments, which characterized the effects on the epidermal growth factor receptor (EGFR) pathway and programmed cell death 1 ligand 1 (PD‐L1) proteins. Through these experiments, we identified the DRD1 gene as a negative regulator of disease progression in NSCLC. We show that DRD1, as well as other DA pathway components, are expressed in normal human lung tissue, and that loss of DRD1 expression through promoter hypermethylation is a common feature in NSCLC patients and is associated with worse survival. At the cellular level, DRD1 affects proliferation by inhibiting the activation of EGFR and mitogen‐activated protein kinase 1/2 (ERK1/2). Interestingly, we also found that DRD1 regulates the expression of PD‐L1 in lung cancer cells. Taken together, these results suggest that DRD1 methylation may constitute a biomarker of poor prognosis in NSCLC patients while other components of this pathway could be targeted to improve response to EGFR‐ and PD‐L1‐targeted therapies.

Dopamine D2 Receptor Agonists Inhibit Lung Cancer Progression by Reducing Angiogenesis and Tumor Infiltrating Myeloid Derived Suppressor Cells.

Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Dopamine Inhibits Group 2 Innate Lymphoid Cell-Driven Allergic Lung Inflammation by Dampening Mitochondrial Activity

Dopamine D1 receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness

The therapeutic effect of DX2 inhibition in nicotine-induced lung cancer progression

Dendrobine Suppresses Tumor Growth by Regulating the PD-1/PD-L1 Checkpoint Pathway in Lung Cancer

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC

Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation

Dopamine Receptor D2 is Correlated with Gastric Cancer Prognosis.

Heme Sequestration Effectively Suppresses the Development and Progression of Both Lung Adenocarcinoma and Squamous Cell Carcinoma

Inhibition of 11Β-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression As Well As the ERK and Mtor Signaling Pathways.

Potential of Targeting TDO2 as the Lung Adenocarcinoma Treatment

Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity.

A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages

Activation of DRD5 (dopamine Receptor D5) Inhibits Tumor Growth by Autophagic Cell Death

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Inhibiting effect of Duffy antigen receptor for chemokines on growth of lung adenocarcinoma A549 xenografts in nude mice and its possible mechanism

ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage

DARS2 Promotes the Occurrence of Lung Adenocarcinoma Via the ERK/c‐Myc Signaling Pathway

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15

Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage